|Bid||7.18 x 3200|
|Ask||7.19 x 800|
|Day's Range||6.84 - 7.22|
|52 Week Range||4.78 - 24.75|
|Beta (3Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Sientra, Inc. (SIEN), a medical aesthetics company, today announced that on September 12, 2019, the Compensation Committee of the Company’s Board of Directors approved equity award grants under the Sientra, Inc. Inducement Plan to 13 new employees. The new employees were granted restricted stock units representing a total of 97,187 shares of common stock. The restricted stock units will vest in three equal annual installments beginning on each individual employee’s hiring date.
Sientra (SIEN) delivered earnings and revenue surprises of -5.80% and 7.18%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Record total net sales of $20.5 million in 2Q19, growth of 17% year over year Breast Products net sales of $11.2 million in 2Q19, growth of 19% year over year Record.
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it will release financial results for the second quarter 2019 after the close of trading on Thursday, August 8, 2019. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers.
Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]
MIAMI, June 21, 2019 /PRNewswire/ -- Bowes Dermatology by Riverchase is pleased to announce the launch of breakthrough technology, miraDry. Bowes Dermatology by Riverchase is one of the first locations in the area to provide miraDry, which is clinically proven to eliminate sweat and odor glands. The miraDry system's unique miraWave™ technology delivers precise microwave energy at the dermal-fat interface, to safely heat and destroy sweat and odor glands and hair follicles.
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the closing of its previously announced underwritten public offering of 17,391,305 shares of its common stock, as well as 2,608,695 additional shares of its common stock pursuant to the full exercise of the option granted to the underwriters. The shares were sold at the public offering price of $5.75 per share and the company estimates the aggregate net proceeds to the company will be approximately $108.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.
Shares of Sientra Inc (NASDAQ: SIEN ) have declined about 25 percent since the company reported its first-quarter results on May 8. Meanwhile, the industry backdrop has improved and the near-term financing ...
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced underwritten public offering. The Company will sell 17,391,305 shares of its common stock at a public offering price of $5.75 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million.
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that it has commenced an underwritten public follow-on offering of approximately $75,000,000 of its common stock to be sold by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.
The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year Provides 2019 Net Sales Outlook of $79 million to $83 million SANTA BARBARA, Calif., May 08, 2019.